Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Contieri

Showing results (31-40 of 138) with videos related to

Pageof 14
Sort By:
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from ChileValentina Grajales, Roberto Contieri, Wei Shen Tan, et al.
BJU International|May 22, 2024
Assessing long-term upgrade risks in recurrent low-grade non-muscle-invasive bladder cancer, can we deintensify the treatment?Alessio Finocchiaro, Marco Paciotti, Roberto Contieri, et al.
The Journal of Urology|August 25, 2023
Reply by AuthorsWei Shen Tan, Roberto Contieri, Nicolò Maria Buffi, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology|February 5, 2025
Advancing Surgical Management of Penile Cancer: Single Port Bilateral Inguinal Lymph Node DissectionSisto Perdonà, Alessandro Izzo, Antonio Tufano, et al.
The Journal of Urology|August 3, 2023
International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active SurveillanceWei Shen Tan, Roberto Contieri, Nicolò Maria Buffi, et al.
BJUI Compass|April 27, 2022
Intravesical gemcitabine as bladder-preserving treatment for BCG unresponsive non-muscle-invasive bladder cancer. Results from a single-arm, open-label studyRodolfo Hurle, Paolo Casale, Emanuela Morenghi, et al.
European Urology Open Science|August 2, 2021
Long-term Follow-up After En Bloc Transurethral Resection of Non-muscle-invasive Bladder Cancer: Results from a Single-center ExperienceMarco Paciotti, Paolo Casale, Piergiuseppe Colombo, et al.
European Urology Focus|January 10, 2024
The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial CarcinomaRoberto Contieri, Alberto Martini, Laura S Mertens, et al.
European Urology Oncology|June 1, 2021
Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non-muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) ExperienceRoberto Contieri, Marco Paciotti, Giovanni Lughezzani, et al.
Minerva Urology and Nephrology|August 2, 2021
Active surveillance for recurrent non-muscle invasive bladder cancer: which lessons have we learned during COVID-19 pandemic?Marco Paciotti, Roberto Contieri, Vittorio Fasulo, et al.
Pageof 14

Showing results (31-40 of 138) with videos related to

Sort By:
Pageof 14
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from ChileValentina Grajales, Roberto Contieri, Wei Shen Tan, et al.
BJU International|May 22, 2024
Assessing long-term upgrade risks in recurrent low-grade non-muscle-invasive bladder cancer, can we deintensify the treatment?Alessio Finocchiaro, Marco Paciotti, Roberto Contieri, et al.
The Journal of Urology|August 25, 2023
Reply by AuthorsWei Shen Tan, Roberto Contieri, Nicolò Maria Buffi, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology|February 5, 2025
Advancing Surgical Management of Penile Cancer: Single Port Bilateral Inguinal Lymph Node DissectionSisto Perdonà, Alessandro Izzo, Antonio Tufano, et al.
The Journal of Urology|August 3, 2023
International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active SurveillanceWei Shen Tan, Roberto Contieri, Nicolò Maria Buffi, et al.
BJUI Compass|April 27, 2022
Intravesical gemcitabine as bladder-preserving treatment for BCG unresponsive non-muscle-invasive bladder cancer. Results from a single-arm, open-label studyRodolfo Hurle, Paolo Casale, Emanuela Morenghi, et al.
European Urology Open Science|August 2, 2021
Long-term Follow-up After En Bloc Transurethral Resection of Non-muscle-invasive Bladder Cancer: Results from a Single-center ExperienceMarco Paciotti, Paolo Casale, Piergiuseppe Colombo, et al.
European Urology Focus|January 10, 2024
The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial CarcinomaRoberto Contieri, Alberto Martini, Laura S Mertens, et al.
European Urology Oncology|June 1, 2021
Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non-muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) ExperienceRoberto Contieri, Marco Paciotti, Giovanni Lughezzani, et al.
Minerva Urology and Nephrology|August 2, 2021
Active surveillance for recurrent non-muscle invasive bladder cancer: which lessons have we learned during COVID-19 pandemic?Marco Paciotti, Roberto Contieri, Vittorio Fasulo, et al.
Pageof 14